{"transactions":[{"id":725218,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T20:29:27.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date."}],"balance_after":62000,"derivative":{"exercise_price":4.25,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0001470831-26-000663","document":"wk-form4_1782505765.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000147083126000663/wk-form4_1782505765.xml","form_type":"4"}},{"id":914013,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":914012,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":914011,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1920,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":61.9,"underlying":"Common Stock","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":914010,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":402,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":914009,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":914008,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:32:40.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":950,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012189","document":"tm265471-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000110465926012189/tm265471-4_4seq1.xml","form_type":"4"}},{"id":920974,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:08:55.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":801000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":801000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":801000},"source":{"system":"sec-edgar","filing":"0000929638-26-000480","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963826000480/form4.xml","form_type":"4"}},{"id":1104571,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:10:56.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":35500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date."}],"balance_after":35500,"derivative":{"exercise_price":1.44,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":35500},"source":{"system":"sec-edgar","filing":"0001662579-25-000043","document":"wk-form4_1750450250.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000043/wk-form4_1750450250.xml","form_type":"4"}},{"id":1119124,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:19:28.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015986","document":"form4-06062025_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588925015986/form4-06062025_080619.xml","form_type":"4"}},{"id":1289121,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:36:39.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":850000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0000929638-25-000476","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963825000476/form4.xml","form_type":"4"}},{"id":1396501,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-10-01T12:02:44.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":5.7,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.50 to $5.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000929638-24-003358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963824003358/form4.xml","form_type":"4"}},{"id":1449187,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-24T22:26:58.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-qualified stock option granted awarded pursuant to the Employment Agreement dated July 22, 2024 between Mr. Cooper and enGene USA, Inc. as an inducement award outside of the enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4).  This option vests at 25% on July 22, 2025, which is the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years, subject to Mr. Cooper's continued service."}],"balance_after":1250000,"derivative":{"exercise_price":8.81,"expiration_date":"2034-07-22","underlying":"Common Shares","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0000929638-24-002577","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963824002577/form4.xml","form_type":"4"}},{"id":1482919,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:46:49.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares underlying this option shall vest and become exercisable on June 7, 2025, with the remainder vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":4.66,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001662579-24-000046","document":"wk-form4_1718138802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000046/wk-form4_1718138802.xml","form_type":"4"}},{"id":1484422,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:05:19.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016182","document":"form4-06102024_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588924016182/form4-06102024_040611.xml","form_type":"4"}},{"id":1858235,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:15:10.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":4.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009606","document":"form4-06122023_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588923009606/form4-06122023_040607.xml","form_type":"4"}},{"id":1978975,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":219350,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\"  was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a \"Company RSU\") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an \"Accelerated 2023 RSU,\"  was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a \"Cancelled 2023 RSU\" was canceled and had no further force or effect."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":219350},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978974,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":155381,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2026-04-14","underlying":"Common Stock","underlying_shares":155381},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978973,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":19422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2026-04-14","underlying":"Common Stock","underlying_shares":19422},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978972,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.48,"expiration_date":"2027-08-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978971,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":123750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978970,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":124000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978969,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":124000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978968,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":93000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978967,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":43027,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":43027},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978966,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"disposition_to_issuer","acquired":false,"shares":132150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a \"Company Option\") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an \"In the Money Option\"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an \"Out of the Money Option\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect."}],"balance_after":0,"derivative":{"exercise_price":26.75,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":132150},"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":1978965,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-02T16:58:41.000Z","date":"2023-03-02","kind":"other","acquired":false,"shares":33094,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027 (the \"Milestone\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the \"Merger Agreement\"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation (\"Parent\"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee (\"Guarantor\"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of March 2, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the \"Closing Amount\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) plus one non-tradeable contractual contingent value right (\"CVR\" and each CVR together with the Closing Amount, the \"Offer Price\"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the \"CVR Agreement\") on or prior to December 31, 2027 (the \"Milestone\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-014778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123014778/doc4.xml","form_type":"4"}},{"id":2043558,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-27T17:28:38.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 33,094 shares of common stock and 219,350 restricted stock units."}],"balance_after":252444,"source":{"system":"sec-edgar","filing":"0001209191-23-005338","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123005338/doc4a.xml","form_type":"4/A","original_submission_date":"2021-01-25"}},{"id":2046266,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-25T20:11:44.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 33,094 shares of common stock and 219,350 restricted stock units."}],"balance_after":252444,"source":{"system":"sec-edgar","filing":"0001209191-23-004953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004953/doc4.xml","form_type":"4"}},{"id":2048523,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-23T17:09:37.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":1057,"price":43.8,"value":46296.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 33,094 shares of common stock and 24,350 restricted stock units."}],"balance_after":57444,"source":{"system":"sec-edgar","filing":"0001209191-23-004448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123004448/doc4.xml","form_type":"4"}},{"id":2058377,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T22:23:31.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":9500,"price":5.12,"value":48640.0,"ownership":{"direct":true},"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001415889-23-000705","document":"form4-01092023_100115.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588923000705/form4-01092023_100115.xml","form_type":"4"}},{"id":2058558,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-09T18:40:07.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":919,"price":19.5764,"value":17990.7116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 31,106 shares of common stock and 27,395 restricted stock units. Includes 534 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2019; 483 shares of common stock acquired under the ESPP on November 30, 2019; 1,205 shares of common stock acquired under the ESPP on May 31, 2020; and 818 shares of common stock acquired under the ESPP on May 31, 2021."}],"balance_after":58501,"source":{"system":"sec-edgar","filing":"0001209191-23-002632","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919123002632/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-25"}},{"id":2132232,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-25T16:00:11.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":919,"price":19.5764,"value":17990.7116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 28,066 shares of common stock and 27,395 restricted stock units."}],"balance_after":55461,"source":{"system":"sec-edgar","filing":"0001209191-22-054485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122054485/doc4.xml","form_type":"4"}},{"id":2202617,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-25T16:09:35.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":929,"price":24.6745,"value":22922.6105,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 25,942 shares of common stock and 30,438 restricted stock units. Includes 1,227 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the \"ESPP\") on May 31, 2022."}],"balance_after":56380,"source":{"system":"sec-edgar","filing":"0001209191-22-043097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122043097/doc4.xml","form_type":"4"}},{"id":2233625,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:05:50.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders."}],"balance_after":19200,"derivative":{"exercise_price":6.19,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0001415889-22-006482","document":"form4-06132022_040638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588922006482/form4-06132022_040638.xml","form_type":"4"}},{"id":2291014,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-25T16:40:29.000Z","date":"2022-04-22","kind":"sale","acquired":false,"shares":907,"price":33.11,"value":30030.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 22,600 shares of common stock and 33,482 restricted stock units."}],"balance_after":56082,"source":{"system":"sec-edgar","filing":"0001209191-22-025523","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122025523/doc4.xml","form_type":"4"}},{"id":2426477,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-25T16:37:23.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":3684,"price":24.8822,"value":91666.0248,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.7811 to $24.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 20,464 shares of common stock and 36,525 restricted stock units."}],"balance_after":56989,"source":{"system":"sec-edgar","filing":"0001209191-22-004801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004801/doc4.xml","form_type":"4"}},{"id":2430014,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-20T16:49:00.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":132150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026."}],"balance_after":132150,"derivative":{"exercise_price":26.75,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":132150},"source":{"system":"sec-edgar","filing":"0001209191-22-004053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919122004053/doc4.xml","form_type":"4"}},{"id":2563841,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-20T16:03:36.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":11973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 17, 2021, the reporting person exercised options to purchase 11,973 shares of common stock and delivered 7,760 shares of common stock held by the reporting person to the issuer to pay the exercise price of the options. The delivery of the shares by the reporting person to pay the exercise price of the options was previously approved by the issuer's compensation committee in accordance with Rule 16b-3 and the issuer has retained the shares delivered to it by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":43027,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":11973},"source":{"system":"sec-edgar","filing":"0001209191-21-056860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121056860/doc4.xml","form_type":"4"}},{"id":2563840,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-20T16:03:36.000Z","date":"2021-09-17","kind":"tax_withholding","acquired":false,"shares":7760,"price":29.61,"value":229773.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 17, 2021, the reporting person exercised options to purchase 11,973 shares of common stock and delivered 7,760 shares of common stock held by the reporting person to the issuer to pay the exercise price of the options. The delivery of the shares by the reporting person to pay the exercise price of the options was previously approved by the issuer's compensation committee in accordance with Rule 16b-3 and the issuer has retained the shares delivered to it by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents 11,973 shares of common stock and 48,700 restricted stock units."}],"balance_after":60673,"source":{"system":"sec-edgar","filing":"0001209191-21-056860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121056860/doc4.xml","form_type":"4"}},{"id":2563839,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-20T16:03:36.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":11973,"price":19.19,"value":229761.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 17, 2021, the reporting person exercised options to purchase 11,973 shares of common stock and delivered 7,760 shares of common stock held by the reporting person to the issuer to pay the exercise price of the options. The delivery of the shares by the reporting person to pay the exercise price of the options was previously approved by the issuer's compensation committee in accordance with Rule 16b-3 and the issuer has retained the shares delivered to it by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 19,733 shares of common stock and 48,700 restricted stock units."}],"balance_after":68433,"source":{"system":"sec-edgar","filing":"0001209191-21-056860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121056860/doc4.xml","form_type":"4"}},{"id":2811096,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-03T21:06:36.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 1, 2021. The shares underlying the option vest over three years, with 1/36 of the shares vesting at the end of each successive month following March 1, 2021."}],"balance_after":30000,"derivative":{"exercise_price":40.2,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-21-001241","document":"form4-03032021_010305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000141588921001241/form4-03032021_010305.xml","form_type":"4"}},{"id":2897451,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-25T17:33:31.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":93000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."}],"balance_after":93000,"derivative":{"exercise_price":34.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001209191-21-005148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005148/doc4.xml","form_type":"4"}},{"id":2897450,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-25T17:33:31.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":48700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 7,760 shares of common stock and 48,700 restricted stock units."}],"balance_after":56460,"source":{"system":"sec-edgar","filing":"0001209191-21-005148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919121005148/doc4.xml","form_type":"4"}},{"id":3104242,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T16:09:51.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 100% on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.22,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001457612-20-000100","document":"wf-form4_159259737339708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761220000100/wf-form4_159259737339708.xml","form_type":"4"}},{"id":3303832,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-23T19:45:40.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021."}],"balance_after":124000,"derivative":{"exercise_price":24.67,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001209191-20-004755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919120004755/doc4.xml","form_type":"4"}},{"id":3458507,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-19T16:07:13.000Z","date":"2019-07-18","kind":"grant","acquired":true,"shares":5625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 100% on the first anniversary of the grant date."}],"balance_after":5625,"derivative":{"exercise_price":3.66,"exercise_date":"2020-07-18","expiration_date":"2029-07-18","underlying":"Common Stock","underlying_shares":5625},"source":{"system":"sec-edgar","filing":"0001457612-19-000111","document":"wf-form4_156356681647121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761219000111/wf-form4_156356681647121.xml","form_type":"4"}},{"id":3687863,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-24T18:21:31.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023."}],"balance_after":124000,"derivative":{"exercise_price":24.04,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001209191-19-005220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919119005220/doc4.xml","form_type":"4"}},{"id":3762968,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-15T16:12:36.000Z","date":"2018-11-13","kind":"purchase","acquired":true,"shares":1026,"price":25.0177,"value":25668.1602,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $24.85 to $25.14. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":7760,"source":{"system":"sec-edgar","filing":"0001209191-18-058716","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118058716/doc4.xml","form_type":"4"}},{"id":3841459,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-08-16T16:26:24.000Z","date":"2018-08-14","kind":"purchase","acquired":true,"shares":200,"price":32.5,"value":6500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2018."}],"balance_after":6734,"source":{"system":"sec-edgar","filing":"0001209191-18-047055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118047055/doc4.xml","form_type":"4"}},{"id":3841458,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-08-16T16:26:24.000Z","date":"2018-08-14","kind":"purchase","acquired":true,"shares":588,"price":31.63,"value":18598.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $31.39\nto $31.83. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":6534,"source":{"system":"sec-edgar","filing":"0001209191-18-047055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118047055/doc4.xml","form_type":"4"}},{"id":3884047,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T20:08:54.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 100% on the first anniversary of the grant date."}],"balance_after":45000,"derivative":{"exercise_price":0.99,"exercise_date":"2019-06-21","expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001457612-18-000071","document":"wf-form4_152997171926543.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761218000071/wf-form4_152997171926543.xml","form_type":"4"}},{"id":3898103,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-11T16:22:48.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":123750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on June 8, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on June 30, 2019 and ending on March 31, 2022."}],"balance_after":123750,"derivative":{"exercise_price":30.68,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":123750},"source":{"system":"sec-edgar","filing":"0001209191-18-036946","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919118036946/doc4.xml","form_type":"4"}},{"id":4226295,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-08-23T16:18:13.000Z","date":"2017-08-21","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in equal installments on the last day of 16 consecutive calendar quarters beginning with September 30, 2017 and ending on June 30, 2021."}],"balance_after":60000,"derivative":{"exercise_price":24.48,"expiration_date":"2027-08-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-049934","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919117049934/doc4.xml","form_type":"4"}},{"id":4280800,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-15T16:55:05.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":15000,"price":5.34,"value":80100.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 100% on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":5.34,"exercise_date":"2018-06-13","expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001676880-17-000002","document":"wf-form4_149756008968125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000167688017000002/wf-form4_149756008968125.xml","form_type":"4"}},{"id":4482827,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-24T17:16:44.000Z","date":"2017-01-20","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in equal installments on the last day of 16 consecutive calendar quarters beginning with March 31, 2017 and ending on December 31, 2020."}],"balance_after":55000,"derivative":{"exercise_price":19.19,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-17-005306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919117005306/doc4.xml","form_type":"4"}},{"id":4565194,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-11-07T18:38:03.000Z","date":"2016-11-03","kind":"grant","acquired":true,"shares":19422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This option was issued in replacement of an option to purchase shares of Albireo Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":19422,"derivative":{"exercise_price":1,"expiration_date":"2026-04-14","underlying":"Common Stock","underlying_shares":19422},"source":{"system":"sec-edgar","filing":"0001209191-16-148717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919116148717/doc4.xml","form_type":"4"}},{"id":4565193,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-11-07T18:38:03.000Z","date":"2016-11-03","kind":"grant","acquired":true,"shares":155381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This option was issued in replacement of an option to purchase shares of Albireo Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is vested and exercisable as to 33.33% of the underlying shares on the grant date, with the remainder vesting and becoming exercisable in 32 equal installments on the first day of each calendar month beginning with December 1, 2016 and ending July 1, 2019."}],"balance_after":155381,"derivative":{"exercise_price":1,"expiration_date":"2026-04-14","underlying":"Common Stock","underlying_shares":155381},"source":{"system":"sec-edgar","filing":"0001209191-16-148717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919116148717/doc4.xml","form_type":"4"}},{"id":4565192,"issuer":{"id":116015,"kind":"organization","name":"ALBIREO PHARMA, INC.","symbol":"ALBO"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-07T18:38:03.000Z","date":"2016-11-03","kind":"grant","acquired":true,"shares":5946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock of Albireo Pharma, Inc. (the \"Issuer\"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited (\"Albireo\") and the holders of Albireo shares and notes convertible into Albireo shares."}],"balance_after":5946,"source":{"system":"sec-edgar","filing":"0001209191-16-148717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1322505/000120919116148717/doc4.xml","form_type":"4"}}]}